Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial

  • Leiter L
  • Teoh H
  • Braunwald E
 et al. 
  • 46

    Readers

    Mendeley users who have this article in their library.
  • 32

    Citations

    Citations of this article.

Abstract

OBJECTIVE: To examine the safety and cardiovascular (CV) effects of saxagliptin in the predefined elderly (>65 years) and very elderly (>75 years) subpopulations of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial., RESEARCH DESIGN AND METHODS: Individuals >40 years (n = 16,492; elderly, n = 8,561; very elderly, n = 2,330) with HbA1c >6.5% (47.5 mmol/mol) and 7.6% (59.6 mmol/mol), the mean change from baseline HbA1c at 2 years was -0.69%, -0.64%, -0.66%, and -0.66% for those >65, 75, and

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Lawrence A. Leiter

  • Hwee Teoh

  • Eugene Braunwald

  • Ofri Mosenzon

  • Avivit Cahn

  • K. M.Prasanna Kumar

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free